Oncolytic Virus Therapy Market

Oncolytic Virus Therapy Market, By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others), By Application (Solid Tumors, Hematological Malignancies), By Delivery Method (Intratumoral Injection, Intravenous Infusion, Intraperitoneal Injection, Others), By End User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Oncolytic virus therapy is a promising approach to cancer treatment that utilizes modified viruses to selectively target and destroy cancer cells while sparing healthy cells. The concept for viruses for cancer treatment dates back to the early 20th century when researchers observed tumor regression in patient with viral infections. The field gained momentum in the 1990s with advancements in genetic engineering, enabling scientists to modify virus to enhance the tumor-specificity and therapeutic efficacy. Oncolytic viruses can infect cancer cells, replicate within them, and induce cell lysis or stimulate immune responses against the tumor. Ongoing research focuses on optimizing viral platforms, developing combination therapies, and expanding the application of oncolytic virus therapy to various cancer types. Collaborations between academia, pharmaceutical companies, and research institutions drive the development of novel oncolytic virus therapies and hold promise for advancing cancer treatment approaches.

Market Dynamics:

The global oncolytic virus therapy market is witnessing strong growth on the account of growing advancements in viral engineering, increasing understanding of cancer biology, successful clinical trial results, and the need for innovative cancer treatments. Moreover, exploring new cancer indications, combining therapies for improved outcomes, personalized medicine approaches, and the development of next-generation viruses with enhanced characteristics are expected to bring bright market opportunities in the near future. The market trends include advancements in virotherapy platforms, targeted delivery systems, immune modulation strategies, and addressing manufacturing, and commercialization challenges in the field.

However, limited clinical evidence, delivery and distribution challenges, and immune response and resistance issues are expected to hamper the market growth. Overcoming these challenges is essential to maximize the efficiency and broader adoption of oncolytic virus therapies.

Key features of the study:

• This report provides in-depth analysis of the global oncolytic virus therapy market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global oncolytic virus therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Targovax, PsiOxus Therapeutics Ltd., Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Transgene SA, VCN Biosciences, Lokon Pharma AB
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global oncolytic virus therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analysing the global oncolytic virus therapy market

Detailed Segmentation:

• Global Oncolytic Virus Therapy Market, Virus Type:
• Adenovirus
• Herpes Simplex Virus (HSV)
• Measles Virus
• Reovirus
• Vaccinia Virus
• Vesicular Stomatitis Virus (VSV)
• Others
• Global Oncolytic Virus Therapy Market, By Application:
• Solid Tumors
• Hematological Malignancies
• Global Oncolytic Virus Therapy Market, By Delivery Type:
• Intratumoral Injection
• Intravenous Infusion
• Intraperitoneal Injection
• Others
• Global Oncolytic virus therapy Market, By End User:
• Hospitals
• Cancer Research Institutes
• Biopharmaceutical Companies
• Global Oncolytic Virus Therapy Market, By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Company Profiles:
• Amgen Inc.
• Merck & Co., Inc.
• Oncolytics Biotech Inc.
• Targovax
• PsiOxus Therapeutics Ltd.
• Vyriad, Inc.
• SillaJen Biotherapeutics
• Cold Genesys Inc.
• Sorrento Therapeutics, Inc.
• Takara Bio Inc.
• Replimune Group Inc.
• Genelux Corporation
• Transgene SA
• VCN Biosciences
• Lokon Pharma AB